IDH突变型胶质瘤患者长期生存的决定因素
该单中心病例对照研究纳入1998至2023年诊断的86例IDH突变型胶质瘤患者,按诊断后6年内死亡或生存至少15年分组,分析短期与长期生存者的特征及预后因素,发现长期生存与CNS WHO 2级、较小肿瘤体积、无对比增强、等待扫描策略及女性相关。
要点
- 长期生存与CNS WHO 2级、较小肿瘤体积、无对比增强、等待扫描策略及女性相关。
- 少突胶质细胞瘤中较大T2肿瘤体积与较短生存相关(HR 1.02;95%CI 1.01-1.05;p=0.04)。
- 星形细胞瘤中无对比增强(HR 0.38;95%CI 0.15-0.94;p=0.04)与等待扫描策略(HR 5.75;95%CI 1.66-26.61;p=0.01)与较长生存相关。
核心结论
- 较大T2肿瘤体积和对比增强可能是较短生存的重要危险因素,而年龄可能不太重要。
- 等待扫描策略可能使部分星形细胞瘤患者获得极好的长期生存。
研究设计与样本
- 单中心病例对照研究,纳入1998年至2023年诊断的86例患者,按诊断后6年内死亡或生存至少15年分组。
- 47例(55%)为星形细胞瘤,39例(45%)为少突胶质细胞瘤,回顾性纳入。
主要发现
- 长期生存与CNS WHO 2级(p<0.01)、较小肿瘤体积(p=0.01)、无对比增强(p<0.01)、等待扫描策略(p<0.01)及女性(p=0.04)相关。
- 少突胶质细胞瘤多因素分析中,较大T2肿瘤体积与较短生存相关(HR 1.02;95%CI 1.01-1.05;p=0.04)。
- 星形细胞瘤患者中,无对比增强(HR 0.38;95%CI 0.15-0.94;p=0.04)和等待扫描策略(HR 5.75;95%CI 1.66-26.61;p=0.01)与较长生存相关。
- 生存者中位随访16.6年(范围15-28.9),数据库关闭时报告34例死亡(40%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Survival times of patients with IDH-mutant gliomas are variable and can extend to decades. Many studies provide progression-free rather than overall survival times and prognostic factors remain ill-defined. Here we explored characteristics of short- and long-term survivors within a cohort of patients with extended follow-up. METHODS: This single-center, case-control study included 86 patients diagnosed between 1998 and 2023 who either died within 6 years after diagnosis or survived at least 15 years. Patient characteristics and prognostic factors were stratified by short- (< 6 years) versus long-term (≥ 15 years) survival. RESULTS: Forty-seven patients (55%) diagnosed with astrocytoma and 39 patients (45%) with oligodendroglioma were included retrospectively. Median follow-up of the survivors was 16.6 years (range 15-28.9). Thirty-four deaths (40%) had been reported at database closure. Long-term survival was associated with CNS WHO grade 2 (p < 0.01), smaller tumor volumes (p = 0.01), lack of contrast enhancement (p < 0.01), wait-and-scan strategies (p < 0.01) and female sex (p = 0.04). In multivariate analyses for oligodendroglioma, larger T2 tumor volumes were associated with shorter survival (HR 1.02; 95% CI 1.01-1.05; p = 0.04). In patients with astrocytoma, lack of contrast enhancement (HR 0.38; 95% CI 0.15-0.94; p = 0.04) and wait-and-scan strategies (HR 5.75; 95% CI 1.66-26.61; p = 0.01) were associated with longer survival. CONCLUSION: Large T2 tumor volume and contrast enhancement may be important risk factors for shorter survival, while age might be of lesser importance. Wait-and-scan strategies may yield excellent long-term survival in some patients with astrocytoma.
引用
- Katzendobler S, Niedermeyer S, Blobner J, et al. Determinants of long-term survival in patients with IDH-mutant gliomas. J Neurooncol. 2024. PMID: 39316316. doi:10.1007/s11060-024-04826-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。